Autopsy report · NCT04316559

Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD

“Drug availability”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 9 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Institute on Drug Abuse (NIDA)

Sponsor type

US National Institutes of Health

Conditions

Opioid-Use Disorder

Interventions

Placebo; TRV734; Oxycodone

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (81% match in meaning)
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  “Drug no longer available” (76% match in meaning)
• Role of Oxytocin in Telling and Detecting Lies
  “Drug not available” (73% match in meaning)
• Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
  “Slow accrual; drug availability” (72% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.